Navigation Links
BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
Date:5/20/2008

in estimates that PEG-PAL could be a potential treatment option for a significant portion of the PKU population.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the development of its product candidate PEG-PAL, and expectations regarding filings with regulatory agencies. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the results of current and planned clinical trials re
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioMarin Announces FDA Approval for Kuvan
2. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
3. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
4. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
5. Go Healthy Initiates Additional Clinical Tests on Cholesterade
6. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
7. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
8. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
9. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
10. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
11. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015  Leaf Healthcare releases ... pressure ulcers place on the healthcare system . ... threat to modern quality healthcare. Research by the ... for Healthcare Research and Quality shows that pressure ... $11 billion a year. The condition is both ...
(Date:7/28/2015)... Mass. , July 28, 2015  Today, Sekisui ... A compact, affordable and efficient instrument, with a broad ... bring significant benefits to the physicians, office or hospital ... of up to 580 tests/hour with ISE, 72 patient ... and has 36 onboard assays (+3 ISE) to meet ...
(Date:7/28/2015)... 28, 2015 Voalte, the leader in ... in purpose-built wireless communications, today announced that Bay ... 104-bed acute-care facility in Webster, Texas ... One™ solution on Spectralink PIVOT™ purpose-built smartphones for ... Voalte a member of its AIMS Partner Program ...
Breaking Medicine Technology:Impact of Pressure Ulcers on Patient Care: Leaf Healthcare Releases White Paper on the Healthcare Burden of Pressure Ulcers 2Impact of Pressure Ulcers on Patient Care: Leaf Healthcare Releases White Paper on the Healthcare Burden of Pressure Ulcers 3Sekisui Diagnostics Announces Launch of SK500 Clinical Chemistry System for US Laboratories 2Bay Area Regional Medical Center Is First to Use Spectralink PIVOT with Voalte One for Caregiver Communication 2Bay Area Regional Medical Center Is First to Use Spectralink PIVOT with Voalte One for Caregiver Communication 3
... ongoing randomized chemotherapy combination trials to ... of specific cancers -, ROCKVILLE, Md., Sept. 2 ... reported initial topline results from,an ongoing randomized Phase 2 ... combination with bortezomib (Velcade) in patients,with advanced multiple myeloma. ...
... Cardiology Continue ... to Innovative Technology, CARLSBAD, Calif., Sept. 2 ... its innovative atrial,fibrillation ablation products were presented by Dr. ... at the European Society of,Cardiology (ESC) congress. One of ...
Cached Medicine Technology:Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 2Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 3Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 4Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 5Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 6Catheter Ablation System for Atrial Fibrillation Shows Reduced Procedure Time, Remarkable Safety Profile and Excellent Outcomes in Two Clinical Studies 2Catheter Ablation System for Atrial Fibrillation Shows Reduced Procedure Time, Remarkable Safety Profile and Excellent Outcomes in Two Clinical Studies 3
(Date:7/28/2015)... ... 2015 , ... Santa Rosa’s The Press Democrat announced its annual report of the very best ... Dr. Heather Furnas took the top spot as the Best Cosmetic Surgeons in Sonoma ... proud to be bestowed such a prestigious title. , The Press Democrat was ...
(Date:7/28/2015)... ... July 28, 2015 , ... A new ... for inmates who continued methadone maintenance treatment (MMT) during incarceration versus those subjected ... relapse to opiate use (1) and more likely to require hospitalization or emergency ...
(Date:7/28/2015)... ... July 28, 2015 , ... Morristown Medical Center, part ... and one of the first five hospitals in the nation, to implant the newly ... on July 23, and all are in good condition. , The CoreValve® Evolut® R ...
(Date:7/28/2015)... Francisco, California (PRWEB) , ... July 28, 2015 , ... ... the results from a recent survey (1) examining consumers’ perspectives on digital ... June 17-24, 2015, covered topics such as innovations in digital health, level of trust ...
(Date:7/28/2015)... FL (PRWEB) , ... July 28, 2015 , ... Dr. ... diseases. , The talk took place from noon to 1 p.m. Tuesday, June 23, ... Panama City, Fla. , Dr. Ahmad is board-certified in colorectal surgery and has ...
Breaking Medicine News(10 mins):Health News:Dr. Canales and Dr. Furnas Honored as Sonoma County’s Best Cosmetic Surgeons 2Health News:Novus Medical Detox Center Analyzes Methadone Study Findings and Implications for Opiate Abuse Treatment 2Health News:Novus Medical Detox Center Analyzes Methadone Study Findings and Implications for Opiate Abuse Treatment 3Health News:Novus Medical Detox Center Analyzes Methadone Study Findings and Implications for Opiate Abuse Treatment 4Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 2Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 3Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 2Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 3Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 4Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 5Health News:Dr. Aziz Ahmad Delivers Talk at Gulf Coast Medical Center 2
... doctors in Tamilnadu said that the doctors in Delhi ... duty. Hence it is asking the doctors to call ... of Institute of Thoracic Medicine, Tambaram, said that though ... proposed reservation in elite educational institutions, it said that ...
... vital that children are administered the correct dosage of ... a hospital.// A new study presented at the Society ... error rates in a program called "LA Kids." ... a Broselow tape (a weight-estimating tool) and report weight-based ...
... get themselves screened for HIV, city-run medical clinics have relaxed ... the new rule, counseling sessions and written informed consent is ... is a verbal consent from the patient. ,This ... relaxed with respect to consent and counseling. Two hospitals and ...
... discovered an embezzlement of nearly Rs.4.4 million from funds ... the fund use were discovered during checking of records ... education. ,The embezzlement was done by four ... 1997 and March 2005. ,Out of this, ...
... for the Indian School Certificate Examination (CISCE) declared the results ... Wednesday// with girls outshining boys for the second consecutive year. ... examination was 96.9 as against 95.29 among boys. Similarly, in ... compared to 91 percent among the boys. ...
... of premature infants from damage. An ongoing study, which ... an early finding in a trial being undertaken to ... of apnoea of prematurity. ,Apnoea of prematurity ... are underdeveloped and the central nervous system, which automatically ...
Cached Medicine News:Health News:Children Need Different Dosage In Cardiac Arrest 2Health News:Caffeine Therapy May Help Protect Lungs Of Premature Babies 2
... field-of-view enables high-quality full-coverage body imaging. New ... architecture. New powerful Quasar Dual gradients designed ... to 80 mT/m SR 200. New ... exploit the power of 3.0T in a ...
... and high power negative lens delivering magnification ... benefit of this system is ease of ... made possible due to a superior depth ... and individual interpupillary adjustment provides stability for ...
... BAK/C cervical interbody fusion system represents a ... of the cervical spine. The system gathers ... implantation. The self-packing of bone into the ... the need to harvest from the iliac ...
Inside and out, the Achieva is designed to unleash a new era, in which the clinical capabilities of MR will further expand....
Medicine Products: